human-immunodeficiency-virus-hiv

Documents about human-immunodeficiency-virus-hiv

• A Multidisciplinary "Integrated Management Team to Improve Maternal-Child Outcomes (IMPROVE)" Intervention to Improve Maternal and Child Outcomes in Lesotho#896970ClinicalTrials.gov
• Utility of the brief Patient Health Questionnaire-2 and Generalized Anxiety Disorder-2 screeners for depression and generalized anxiety symptom identification in people with human immunodeficiency virus.#9940PubMed
• Maternal-to-child- transmission of human immunodeficiency virus in maternal preterm premature rupture of the membranes: A Systematic review#372633ULRR
• Immunophenotypic and Molecular Features of TP53 in Diffuse Large B-Cell Lymphoma (DLBCL)#477926WIReDSpace
• KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)#900595ClinicalTrials.gov
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)#872401ClinicalTrials.gov
• Infrastructural and human-resource factors associated with return of infant HIV test results to caregivers: secondary analysis of a nationally representative situational assessment, South Africa, 2010#372701University of Pretoria Repository
• Evaluation of Problem Management Plus in Pregnant Women With HIV in Kenya#867891ClinicalTrials.gov
• Gender identity and HIV risk among men who have sex with men in Cape Town, South Africa#355835University of Pretoria Repository
• Table 1_Multidisciplinary management of severe odontogenic maxillofacial multi-space infection in a patient with HIV–syphilis coinfection and advanced immunosuppression: a case report.docx#635014Figshare
• A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)#180206ClinicalTrials.gov
• A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients#1030008ClinicalTrials.gov
• A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59#868823ClinicalTrials.gov
• ComBaCaL HIV Prevention TwiCs#804089ClinicalTrials.gov
• Barriers to access and use of sexual reproductive health and human immunodeficiency virus services among adolescent girls and young women in Maputo City, Mozambique#306919African Journals Online
• A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir#882701ClinicalTrials.gov
• Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants#888129ClinicalTrials.gov
• HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection#879866ClinicalTrials.gov